Antipsychotics and OCD: Boon or Bane?

Sir,
Some of the major changes in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition are the relocation of obsessive-compulsive disorder (OCD) and acknowledging a delusional specifier. This should be borne in mind while working the differential for OCD/psychosis interface which might also entail – obsessive-compulsive symptoms (OCS) as a psychotic prodroma, schizotypal PD with superimposed OCD, Asperger’s syndrome, “schizo-obsessive” disorder, and atypical antipsychotic (AAP)-induced OCS.

AAPs are a common augmentative strategy in treatment-resistant OCD. Moreover, some have contended that dopamine blockade is critical to facilitate 5-hydroxytryptamine (5HT) transmission in the cortico-striato-pallido-thalamo-cortical neurocircuitry in OCD. Indicators to use this tactic might include tics, schizotypal personality disorder, autism spectrum disorder, poor insight, and mood instability. Of the AAPs, best available evidence is for risperidone as shown in a meta-analysis by Dold et al.[1] and also aripiprazole as demonstrated by Ducasse et al.[2] in a meta-regression analysis. This would translate clinically into a lower threshold to employ AAPs in the pharmacotherapy of OCD earlier than later.

Paradoxically, APPs have been notoriously reported to induce de novo or exacerbate preexisting OCD in schizophrenia. This seems to be related chiefly to the primary diagnosis. It has also been reported in bipolar mood disorders, intellectual disability, delusional disorder, and psychotic depression. Lim et al.[3] have found an incidence of 12% of AAPs-induced OCS in a cohort of schizophrenia and schizo-affective disorder (n = 209).

Since 5HT dysregulation is central to OCD neurobiology, it seems that AAPs by virtue of 5HT2A antagonism might mechanistically induce these OCS as demonstrated by Zink.[4]

Agents with higher 5HT2A affinity seem to have a stronger potential to induce OCD notably clozapine. Lin et al.[5] have found that patients developing clozapine-induced OCS had higher concentrations of clozapine and norclozapine. Kwon et al.[6] have demonstrated the association between SLC1A1 gene and AAPs-induced OCS in schizophrenia.

Poyurovsky et al.[7] have proposed clinical criteria to diagnose AAPs-induced OCS. These include male preponderance, preexisting OCS in schizophrenia, compulsions, during the 1st week of treatment, and typically with higher doses.

Treatment typically entails dose reduction or entirely discontinuation of culprit AAP, introduction of selective serotonin reuptake inhibitors (SSRIs), or both. Aripiprazole and amisulpride by virtue of unique secondary pharmacodynamic properties remain viable options.

To pull it together, the use of APP, especially risperidone or aripiprazole, ab initio, is highly indicated in cases of bona fide OCD, earlier rather than later and more so if coupled with clinical correlates highlighted above (e.g., tic-related OCD). On the other hand, if the primary diagnosis is schizophrenia and patients phenomenologically endorse OCS, which
is commonplace in 5%-45%, then clinicians might opt to try aripiprazole or the substituted benzamide amisulpride, and closely clinically monitoring for OCS accentuation, in which case, add-on SSRI might be a reasonable course of action, given additive neuroprotective actions by virtue of SSRI-enhanced dentate gyrus neurogenesis. A caution, however, should be exercised here regarding significant pharmacokinetic interactions between SSRIs known to be potent cytochrome P450 inhibitors (e.g., fluoxetine on 2D6) and AAPs (e.g., risperidone as a substrate for 2D6).

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Ahmed Naguy
Al-Manara CAP Centre, Kuwait Centre for Mental Health, Shuwaikh, Kuwait

Address for correspondence: Dr. Ahmed Naguy
Al-Manara CAP Centre, Kuwait Centre for Mental Health, Jamal Abdul Nasser Street, Shuwaikh, Kuwait.
E-mail: ahmednagy@hotmail.co.uk

REFERENCES
1. Dold M, Aigner M, Lanzengerber R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 2013;16:557-74.
2. Ducasse D, Boyer L, Michel P, Louンドou A, Macgregor A, Micoulaud-Franchi JA, et al. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: A metaregression analysis. Psychopharmacology (Berl) 2014;231:3765-70.
3. Lim M, Park DY, Kwon JS, Joo YH, Hong KS. Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol 2007;27:712-3.
4. Zink M. Comorbid obsessive-compulsive symptoms in schizophrenia: Insight into pathomechanisms facilitates treatment. Adv Med 2014;2014:317980.
5. Lin SK, Su SF, Pan CH. Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther Drug Monit 2006;28:303-7.
6. Kwon JS, Joo YH, Nam HJ, Lim M, Cho EY, Jung MH, et al. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 2009;66:1233-41.
7. Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: Clinical characteristics and treatment. CNS Drugs 2004;18:989-1010.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Naguy A. Antipsychotics and OCD: Boon or Bane?. Indian J Psychol Med 2017;39:830-1.

© 2017 Indian Psychiatric Society | Published by Wolters Kluwer - Medknow